EFTA Document EFTA01368452

819.76/19.86K From: Vahe Stepanian Sent: 6/16/2015 10:02:02 AM To: Jeffrey Epstein Deevacation@gmailcom) CC: Daniel Sabba • Ariane Dwyer Stewart Oldfield ; Richard Kahn Subject: AAVL: (BN) Avalanche Drops as Gene Therapy Trial Miss High Expectation [CI Classification: Confidential Jeffrey - we are following up with the below news regarding AAVL. The stock is trading down $19.11 to $19.7657 per the Bloomberg screenshot below. Please let us know how you would like to proceed with your position. Thank you, Vahe ARYL US I 19.765/ 14. I A 4 At 9:42 Vol 2 757 437 0 19.22Q H 21.000 I. 19.221 Val 55.75211 1x3 High 60.08 on 01/07/15 tow 17.00 on 07/30/14 Average 37.4273 298,642 Net c,.:; 2.75 16.181. UST ThstlYeT&T NAME t, 05129/ IS 37.28 333,767 • 31 A 7 r!, 051214/15 37.26 412415 0°,/07/ 1S 33.04 • 057.77/1'. 39.13 444,839 • •'..a )6/1'4 33.30 19.75 2,696,176 Tu 05/26/15 37.02 295,552 b. 05;31"/Th 29.44 38.88 7,075,961 II.; 05;25715 31.00 06/72/75 41.40 481,003 !! !! 05/77/15 38.03 704,109 Fr 05/01/1li 33.17 in 06/11/1.5. 40.79 315,535 lb 05721115 3893 576,821 lb 04730/15 3126 1,6/ /0/ P, 39.73 358.955.:; OS/20/74 .39.05 382,443 ',:<, 04/29/1!, 35.04 lu 05709715 37.03 378,175 lb 05/19/3$ 38.24 352373 III 04/28/15 3632 I' , 06/08/15 37.70 340,492 I. 05,71,811r, 36.67 373,114 i! ! 04/27/15 35.36 ti 06/0S/15 40.28 343,172 i (Th,13S/15 35.10 376,321 i r 44/24/ IS 31.57 lb 0004/15 38.82 244,332 lb 05/14/15 35.95 303.062 IF 04/73/15 38.49 us, 06/63w, 37.51 397,270::" °YEW!, 35.65 234,3061h= 04727/V, 38.93 TO 06/02/15 37.52 256,238 16 05/12115 33.88 196,5681e 04/71/15 3935 hi; 06/01/15 37,24 306,9591b> 0571); V. 34.85 761,310 !!!!! 01/70/11, 39.57 778,553 214,411 460,598 236,054 488,536 767,787 336,730 749,917 309,973 510,565 166,943 161,093 246,164 216,979 718,717 Original Message From: Vahe Stepanian (DEUTSCHE BANK SECURI) [mailto Sent: Tuesday, June 16, 2015 9:41 AM Subject: (BN) Avalanche Drops as Gene Therapy Trial Miss High Expectation (BN) Avalanche Drops as Gene Therapy Trial Miss High Expectations (1) This has been prepared solely for informational purposes. It is not an offer, recommendation or solicitation to buy or sell, nor is it an official confirmation of terms. It is based on information generally available to the public from sources believed to be reliable. No representation is made that it is accurate or complete or that any returns indicated will be achieved. Changes to assumptions may have a material impact on any returns detailed. Past performance is not indicative of future returns. Price and availability are subject to change without notice. Additional information is available upon CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e) DB-SDNY-0060193 CONFIDENTIAL PROT1 PROT0